Many cell and gene therapies can prove difficult for reimbursement due to their high cost and complicated risk-to-benefit ratio. When that therapy is a lifesaving medication, it makes the issue of patient access paramount.
In the latest case study from UBC, we discuss how our patient access team worked incredibly closely with the sponsor to create a program tailored to this unique pediatric population and therapy. This spinal muscular atrophy (SMA) gene therapy provided unique challenges for our case managers. Find out how our team overcame:
Download the case study today using the form to the right.
Subscribe Now
Subscribe Now
Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.
Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.
Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.
President & Chief Executive Officer
Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.
With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.